文献速递糖尿病肥胖与代谢综合征性腺与生殖内分泌

睾酮治疗、体重减轻与男性健康相关生活质量及心理社会功能:一项为期2年的随机对照试验

Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

该研究为T4DM试验的二次分析,纳入来自澳大利亚6个中心、≥50岁且2型糖尿病高风险的男性1007例,随机接受注射用十一酸睾酮或安慰剂,背景为社区生活方式干预。24个月时多数HR-QOL/心理社会功能指标组间无差异,睾酮较安慰剂改善主观社会地位和一致性感;无论分组,体重下降越大与心理生活质量、掌控感和主观社会地位改善相关。结论:生活方式干预诱导的体重减轻在更多维度改善HR-QOL和心理社会功能。

要点

  • 在无病理性性腺功能减退的2型糖尿病高风险男性中,睾酮治疗仅改善主观社会地位和一致性感。
  • 无论治疗分组,体重下降越大与心理生活质量、掌控感和主观社会地位改善相关。
  • 体重和腰围下降幅度可由基线躯体功能、抑郁症状和一致性感预测。

核心结论

  • 在糖尿病预防试验中,生活方式干预诱导的体重减轻在更多维度改善HR-QOL和心理社会功能,优于睾酮治疗。
  • 体重和腰围下降幅度可由基线躯体功能、抑郁症状和一致性感预测。

研究设计与样本

  • T4DM试验的二次分析,为期2年随机对照睾酮治疗试验,旨在预防或逆转新诊断的2型糖尿病。
  • 纳入来自澳大利亚6个中心、≥50岁且2型糖尿病高风险的男性,共1007例随机分组。
  • 干预为注射用十一酸睾酮或匹配安慰剂,背景为社区生活方式项目。
  • 648例(64%)具有基线和2年时所有HR-QOL/心理社会功能评估的完整数据。

主要发现

  • 24个月内,多数HR-QOL/心理社会功能指标在治疗组间无差异。
  • 睾酮治疗较安慰剂改善主观社会地位和一致性感。
  • 基线HR-QOL/心理社会功能指标不能预测睾酮治疗对血糖结局(T4DM主要终点)的影响。
  • 无论治疗分组,体重下降越大与心理生活质量、掌控感和主观社会地位改善相关。
  • 基线躯体功能较好、一致性感较强和抑郁症状较少的男性,体重下降幅度更大,腰围变化类似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the effect of testosterone vs placebo treatment on health-related quality of life (HR-QOL) and psychosocial function in men without pathologic hypogonadism in the context of a lifestyle intervention. DESIGN, SETTING, PARTICIPANTS: Secondary analysis of a 2-year randomized controlled testosterone therapy trial for prevention or reversal of newly diagnosed type 2 diabetes, enrolling men ≥ 50 years at high risk for type 2 diabetes from 6 Australian centers. INTERVENTIONS: Injectable testosterone undecanoate or matching placebo on the background of a community-based lifestyle program. MAIN OUTCOMES: Self-reported measures of HR-QOL/psychosocial function. RESULTS: Of 1007 participants randomized into the Testosterone for Type 2 Diabetes Mellitus (T4DM) trial, 648 (64%) had complete data available for all HR-QOL/psychosocial function assessments at baseline and 2 years. Over 24 months, while most measures were not different between treatment arms, testosterone treatment, compared with placebo, improved subjective social status and sense of coherence. Baseline HR-QOL/psychosocial function measures did not predict the effect of testosterone treatment on glycemic outcomes, primary endpoints of T4DM. Irrespective of treatment allocation, larger decreases in body weight were associated with improved mental quality of life, mastery, and subjective social status. Men with better baseline physical function, greater sense of coherence, and fewer depressive symptoms experienced greater associated decreases in body weight, with similar effects on waist circumference. CONCLUSION: In this diabetes prevention trial, weight loss induced by a lifestyle intervention improved HR-QOL and psychosocial function in more domains than testosterone treatment. The magnitude of weight and waist circumference reduction were predicted by baseline physical function, depressive symptomology, and sense of coherence.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Grossmann M, Robledo KP, Daniel M, et al. Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial. J Clin Endocrinol Metab. 2024. PMID: 38335137. doi:10.1210/clinem/dgae085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。